Charles River reports 34% revenue spike in Q2

By The Science Advisory Board staff writers

August 4, 2021 -- Charles River Laboratories reported a 34% increase in revenue for the second quarter of 2021 compared to the same period during the previous year.

For the second quarter of 2021, the company reported revenue of $914.6 million. During the same quarter in 2020, company revenue was $682.6 million. Acquisitions, the impact of foreign currency translation, and contributions from Charles River's three business segments were attributed to the revenue growth.

Revenue from the Manufacturing Solutions segment spiked 60% from $123.5 million in the second quarter of 2020 to $197.8 million during the same period of 2021. Approximately 28% of revenue in this segment was attributed to the acquisition of Cognate BioServices, according to the company.

The Research Models and Services segment brought in $176.7 million in revenue in the second quarter. This was a 51.6% increase from the segment's $116.5 million in revenue generated in the second quarter of 2020. Finally, revenue from the Discovery and Safety Assessment segment rose 22% from $442.6 million in the second quarter of 2020 to $540.1 million in the same quarter of 2021.

Based on the company's strong second-quarter financial performance, Charles River is boosting its forecast for 2021. It expects to achieve 2021 revenue growth of 20.5% to 22.5%, an increase from the previous projected growth of 19% to 21%.

Charles River completes Vigene acquisition
Charles River Laboratories has completed its acquisition of Vigene for $292.5 million in cash. In addition to the initial purchase price, the transaction...
Charles River to acquire Vigene Biosciences for $293M
Charles River Laboratories has entered into an agreement to acquire Vigene Biosciences, a U.S-based gene therapy contract development and manufacturing...
Charles River Laboratories shows strong revenue, earnings gains in Q1
Sales gains across all three of its business segments helped drive Charles River Laboratories to a 16.6% increase in revenue in its 2021 first quarter.
Charles River to provide clients with Valence AI tech
Charles River Laboratories and Valence Discovery have formed a strategic partnership to provide clients with access to Valence's artificial intelligence...
Charles River to pay $875M to buy Cognate BioServices
Charles River Laboratories has signed a deal to pay about $875 million in cash to acquire cell and gene manufacturer Cognate BioServices.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter